Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 15/20 | 0.45 |
| ▸ | MAPK11 | Q15759 | 4/20 | 0.42 |
| ▸ | SRC | P12931 | 3/20 | 0.38 |
| ▸ | BRAF | P15056 | 3/20 | 0.38 |
| ▸ | KDR | P35968 | 3/20 | 0.38 |
| ▸ | CSNK1E | P49674 | 3/20 | 0.36 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.36 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.36 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.35 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | RAF1 | P04049 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5252370 | 0.93 | MAPK14 (0.42) | MAPK14MAPK11SRCBRAFKDR | |
| SCHEMBL5249559 | 0.88 | MAPK14 (0.47) | MAPK14MAPK11SRCBRAFKDR | |
| SCHEMBL5251675 | 0.88 | MAPK14 (0.47) | MAPK14MAPK11SRCBRAFKDR | |
| SCHEMBL5253645 | 0.87 | MAPK14 (0.47) | MAPK14MAPK11SRCBRAFKDR | |
| SCHEMBL5252263 | 0.84 | MAPK14 (0.44) | MAPK14MAPK11SRCBRAFKDR | |
| SCHEMBL5249678 | 0.82 | MAPK14 (0.62) | MAPK14MAPK11SRCBRAFKDR | |
| SCHEMBL5253180 | 0.81 | MAPK14 (0.47) | MAPK14MAPK11MAPK13MAPK12 | |
| SCHEMBL5250775 | 0.80 | MAPK14 (0.43) | MAPK14MAPK11CSNK1ECSNK1DMAPK13 | |
| SCHEMBL5249661 | 0.80 | MAPK14 (0.43) | MAPK14MAPK11CSNK1EMAPK13MAPK12 | |
| SCHEMBL5765709 | 0.80 | MAPK14 (0.67) | MAPK14MAPK11MAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1361225-B1 | COMPOUNDS SUBSTITUTED WITH BICYCLIC AMINO GROUPS | SANKYO CO (JP) | 2007-11-07 | — | — | EP | claimed |
| US-7091352-B2 | Compounds substituted with bicyclic amino groups | SANKYO COMPANY, LIMITED (JP) | 2006-08-15 | — | — | US | claimed |
| US-20040147525-A1 | Compounds substituted with bicyclic amino groups | SANKYO COMPANY, LIMITED (JP) | 2004-07-29 | — | — | US | claimed |
| EP-1361225-A1 | COMPOUNDS SUBSTITUTED WITH BICYCLIC AMINO GROUPS | Sankyo Company, Limited (JP) | 2003-11-12 | — | — | EP | claimed |
| EP-1361225-B1 | COMPOUNDS SUBSTITUTED WITH BICYCLIC AMINO GROUPS | SANKYO CO (JP) | 2007-11-07 | — | — | EP | disclosed |
| US-7091352-B2 | Compounds substituted with bicyclic amino groups | SANKYO COMPANY, LIMITED (JP) | 2006-08-15 | — | — | US | disclosed |
| US-20040147525-A1 | Compounds substituted with bicyclic amino groups | SANKYO COMPANY, LIMITED (JP) | 2004-07-29 | — | — | US | disclosed |
| EP-1361225-A1 | COMPOUNDS SUBSTITUTED WITH BICYCLIC AMINO GROUPS | Sankyo Company, Limited (JP) | 2003-11-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147525-A1 | Compounds substituted with bicyclic amino groups | IL2, IL1B, IL4I1 | MAPK14 1355/4885MAPK11 1447/4885SRC 390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.